Observational studyPediatric pulmonology2026
Effectiveness of Continuous Levalbuterol Versus Albuterol During a National Shortage: A Retrospective Observational Cohort Study.
Observational study in Pediatric pulmonology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBronchospasm requiring continuous inhaled albuterol is a common reason for pediatric intensive care unit (PICU) admission. Albuterol's racemic composition may contribute to adverse effects; therefore, levalbuterol [(R)-albuterol] may be used. This study aimed to determine if continuous inhaled levalbuterol is associated with a shorter duration of continuous inhaled bronchodilator therapy and less tachycardia compared to albuterol in PICU patients.
methodsThis study utilized two periods of exclusive continuous inhaled levalbuterol use due to an albuterol shortage. PICU encounters receiving ≥ 12 h of continuous inhaled levalbuterol during those periods were compared to encounters receiving albuterol in the interim. Therapy duration and % change in median heart rate (HR) at 6-h epochs were compared between groups, and multilevel mixed effects models were created.
resultsIn 686 encounters, there was no difference in therapy duration between levalbuterol and albuterol groups (31.3 vs. 28.7 h, p = 0.22). There was no difference in % change in median HR at 6 (-1.0% vs. -1.3%, p = 0.54), 12 (-1.6% vs. -2.7%, p = 0.28), or 18 h (-2.5% vs. -4.1%, p = 0.38) from therapy initiation. Levalbuterol was not associated with therapy duration adjusting for age, technology dependence, respiratory rate category, and number of continuous intravenous bronchodilators (p = 0.13). Levalbuterol was not associated with % change in median HR at 12 h following therapy initiation after adjusting for age and respiratory rate category (p = 0.99).
conclusionContinuous inhaled levalbuterol was not associated with shorter therapy duration or lower HR compared to albuterol in PICU patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.